Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks Loom

Novartis (NYSE:NVS) executives outlined a slate of upcoming drug-trial results and regulatory discussions across immunology, cardiovascular disease, oncology and neuroscience, while reiterating sales ambitions for several established medicines.

Among the company’s priorities are securing a label for Sjögren’s disease candidate ianalumab, advancing cardiovascular outcomes studies for cholesterol drug Leqvio and defending breast cancer treatment Kisqali against potential competition. Executives also discussed setbacks, including the decision not to submit cardiovascular candidate pelacarsen after a negative outcomes trial.

Immunology: Ianalumab Label and Cosentyx Outlook

Angelika Jahreis, global head of immunology development, said Novartis is discussing ianalumab’s potential Sjögren’s label with the U.S. Food and Drug Administration. The agency has asked which patient subsets respond best, she said, but the company has not seen a proposed label and cannot yet provide details.

Jahreis said patients in ianalumab trials began with an average systemic disease activity score of approximately 12.5, which fell to about five after two years of treatment. She said 23% had a score of zero after two years. The studies focused on patients with systemic manifestations, although some also experienced improvements in dryness and salivary flow.

Christy Siegel, senior vice president and therapeutic area head of immunology, said Novartis remains confident in its multibillion-dollar outlook for ianalumab in Sjögren’s, though she expects a steady ramp-up as awareness of the disease develops. A separate study in patients with predominantly symptomatic disease could support a broader label if needed, Jahreis said.

Siegel also reiterated confidence that Cosentyx will deliver $8 billion in sales in 2027. She cited its position in hidradenitis suppurativa, or HS, and potential growth from its polymyalgia rheumatica indication, while noting that the latter market will take time to develop.

For the oral drug remibrutinib in HS, Jahreis said two studies would read out in a few weeks. She said an oral treatment could potentially be used before biologics, even if its efficacy is more modest.

Cardiovascular Pipeline and Leqvio Trials

Patrick Horber, president of international, said Novartis does not plan to submit pelacarsen after the HORIZON study showed a 78% reduction in lipoprotein(a) but no reduction in cardiovascular events. The company is reviewing the data and plans to apply its findings to the rest of its lipoprotein(a) portfolio.

Novartis expects the first Leqvio cardiovascular outcomes study, ORION-4, to read out first, followed by VICTORION-2-PREVENT, or V2P, in 2027. Ruchira Glaser, development unit head for cardiovascular, renal and metabolic diseases, said V2P is projected around the middle of the year, closer to the second half.

Glaser said Novartis remains confident in Leqvio’s benefits, although the pandemic introduced some uncertainty into ORION-4. The company plans to submit both studies to regulators for inclusion in the drug’s label. Dianne Auclair Rocha, U.S. therapeutic area head for cardiovascular, renal and metabolic diseases, said U.S. commercial modeling has been anchored to V2P.

For abelacimab, being studied in patients with atrial fibrillation who are unsuitable for oral anticoagulation because of bleeding risk, Glaser said the LILAC trial is expected to read out around the middle of 2027. An interim review included assessments for futility and overwhelming efficacy, with a deliberately high threshold for stopping early. No further interim analysis is planned, she said.

Oncology Competition and Pelabresib Talks

Novartis remains confident in its $10 billion peak sales guidance for Kisqali, said Chief Commercial Officer Reshema Kemps-Polanco, despite analyst questions about potential competition from giredestrant. She cited Kisqali’s market position, reimbursement and longer-term data, and argued that combining a CDK4/6 inhibitor with hormonal therapy remains important for patients needing more intensive treatment.

Chief Medical Officer Shreeram Aradhye said Novartis is in active discussions with the FDA about whether pelabresib could reach U.S. patients through accelerated approval based on MANIFEST-2 data. If not, the ongoing MANIFEST-3 study would form the basis of a U.S. filing. Novartis has submitted the drug in Europe based on MANIFEST-2, he said.

Neuroscience: Remibrutinib and Gene Therapy

Victor Bultó, president of the U.S. business, said Novartis sees a more than $4 billion opportunity for remibrutinib in relapsing multiple sclerosis. Nazem Atassi, head of neuroscience development, said two phase 3 trials met their primary and individual secondary endpoints, but a pooled analysis missed statistical significance on three-month confirmed disability progression. The company plans to discuss the full progression data with regulators.

Atassi also said Novartis is reviewing data after a phase 3 study of del-desiran in myotonic dystrophy type 1 did not reproduce the phase 2 signal on its primary endpoint. The company intends to develop an optimized trial proposal for discussion with the FDA.

On gene therapy Zolgensma, Atassi said a handful of tumors have been reported among more than 6,000 treated patients. In two cases, he said, vector integration occurred in or near an oncogene. Novartis is working with the FDA on potential label changes; Atassi said the agency’s initial assessment indicated that the treatment’s benefits outweigh its risks.

About Novartis (NYSE:NVS)

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.